Oncology Drugs Industry Research Report 2023

Oncology Drugs Industry Research Report 2023


Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

Highlights

The global Oncology Drugs market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.
The Oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights


In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences

Product Type Insights

Global markets are presented by Oncology Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Oncology Drugs are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Oncology Drugs segment by Type

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Oncology Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Oncology Drugs market.
Oncology Drugs Segment by Application

Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Oncology Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Oncology Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncology Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Oncology Drugs by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
2.3 Oncology Drugs by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Blood Cancer
2.3.3 Breast Cancer
2.3.4 Gastrointestinal Cancer
2.3.5 Prostate Cancer
2.3.6 Respiratory or Lung Cancer
2.3.7 Others
2.4 Assumptions and Limitations
3 Oncology Drugs Breakdown Data by Type
3.1 Global Oncology Drugs Historic Market Size by Type (2018-2023)
3.2 Global Oncology Drugs Forecasted Market Size by Type (2023-2028)
4 Oncology Drugs Breakdown Data by Application
4.1 Global Oncology Drugs Historic Market Size by Application (2018-2023)
4.2 Global Oncology Drugs Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Oncology Drugs Market Perspective (2018-2029)
5.2 Global Oncology Drugs Growth Trends by Region
5.2.1 Global Oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Oncology Drugs Historic Market Size by Region (2018-2023)
5.2.3 Oncology Drugs Forecasted Market Size by Region (2024-2029)
5.3 Oncology Drugs Market Dynamics
5.3.1 Oncology Drugs Industry Trends
5.3.2 Oncology Drugs Market Drivers
5.3.3 Oncology Drugs Market Challenges
5.3.4 Oncology Drugs Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Oncology Drugs Players by Revenue
6.1.1 Global Top Oncology Drugs Players by Revenue (2018-2023)
6.1.2 Global Oncology Drugs Revenue Market Share by Players (2018-2023)
6.2 Global Oncology Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Oncology Drugs Head office and Area Served
6.4 Global Oncology Drugs Players, Product Type & Application
6.5 Global Oncology Drugs Players, Date of Enter into This Industry
6.6 Global Oncology Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Oncology Drugs Market Size (2018-2029)
7.2 North America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Oncology Drugs Market Size by Country (2018-2023)
7.4 North America Oncology Drugs Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Oncology Drugs Market Size (2018-2029)
8.2 Europe Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Oncology Drugs Market Size by Country (2018-2023)
8.4 Europe Oncology Drugs Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Oncology Drugs Market Size (2018-2029)
9.2 Asia-Pacific Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Oncology Drugs Market Size by Country (2018-2023)
9.4 Asia-Pacific Oncology Drugs Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Oncology Drugs Market Size (2018-2029)
10.2 Latin America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Oncology Drugs Market Size by Country (2018-2023)
10.4 Latin America Oncology Drugs Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Oncology Drugs Market Size (2018-2029)
11.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Oncology Drugs Market Size by Country (2018-2023)
11.4 Middle East & Africa Oncology Drugs Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Drugs Introduction
11.1.4 Roche Revenue in Oncology Drugs Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Oncology Drugs Introduction
11.2.4 Celgene Revenue in Oncology Drugs Business (2017-2022)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Oncology Drugs Introduction
11.3.4 Novartis Revenue in Oncology Drugs Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncology Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Oncology Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Oncology Drugs Business (2017-2022)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Oncology Drugs Business (2017-2022)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Oncology Drugs Introduction
11.7.4 AstraZeneca Revenue in Oncology Drugs Business (2017-2022)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oncology Drugs Introduction
11.8.4 Pfizer Revenue in Oncology Drugs Business (2017-2022)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Oncology Drugs Introduction
11.9.4 Amgen Revenue in Oncology Drugs Business (2017-2022)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Oncology Drugs Introduction
11.10.4 Eli Lilly Revenue in Oncology Drugs Business (2017-2022)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Oncology Drugs Introduction
11.11.4 AbbVie Revenue in Oncology Drugs Business (2017-2022)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Oncology Drugs Introduction
11.12.4 Takeda Revenue in Oncology Drugs Business (2017-2022)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Detail
11.13.2 Astellas Business Overview
11.13.3 Astellas Oncology Drugs Introduction
11.13.4 Astellas Revenue in Oncology Drugs Business (2017-2022)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Oncology Drugs Introduction
11.14.4 Ipsen Revenue in Oncology Drugs Business (2017-2022)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Oncology Drugs Introduction
11.15.4 Sanofi Revenue in Oncology Drugs Business (2017-2022)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Detail
11.16.2 Bayer Business Overview
11.16.3 Bayer Oncology Drugs Introduction
11.16.4 Bayer Revenue in Oncology Drugs Business (2017-2022)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Detail
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Oncology Drugs Introduction
11.17.4 Biogen Idec Revenue in Oncology Drugs Business (2017-2022)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Drugs Introduction
11.18.4 Teva Revenue in Oncology Drugs Business (2017-2022)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Oncology Drugs Introduction
11.19.4 Otsuka Revenue in Oncology Drugs Business (2017-2022)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Oncology Drugs Introduction
11.20.4 Eisai Revenue in Oncology Drugs Business (2017-2022)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Detail
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Oncology Drugs Introduction
11.21.4 Merck KGaA Revenue in Oncology Drugs Business (2017-2022)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Detail
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Oncology Drugs Introduction
11.22.4 Gilead Sciences Revenue in Oncology Drugs Business (2017-2022)
11.22.5 Gilead Sciences Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Oncology Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Oncology Drugs Revenue Market Share by Type (2018-2023)
Table 7. Global Oncology Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Oncology Drugs Revenue Market Share by Type (2024-2029)
Table 9. Global Oncology Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Oncology Drugs Revenue Market Share by Application (2018-2023)
Table 11. Global Oncology Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Oncology Drugs Revenue Market Share by Application (2024-2029)
Table 13. Global Oncology Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Oncology Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Oncology Drugs Market Share by Region (2018-2023)
Table 16. Global Oncology Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Oncology Drugs Market Share by Region (2024-2029)
Table 18. Oncology Drugs Market Trends
Table 19. Oncology Drugs Market Drivers
Table 20. Oncology Drugs Market Challenges
Table 21. Oncology Drugs Market Restraints
Table 22. Global Top Oncology Drugs Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Oncology Drugs Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Oncology Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Oncology Drugs, Headquarters and Area Served
Table 26. Global Oncology Drugs Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Oncology Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Oncology Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Oncology Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Oncology Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Oncology Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Oncology Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Oncology Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Roche Company Detail
Table 46. Roche Business Overview
Table 47. Roche Oncology Drugs Product
Table 48. Roche Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 49. Roche Recent Development
Table 50. Celgene Company Detail
Table 51. Celgene Business Overview
Table 52. Celgene Oncology Drugs Product
Table 53. Celgene Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 54. Celgene Recent Development
Table 55. Novartis Company Detail
Table 56. Novartis Business Overview
Table 57. Novartis Oncology Drugs Product
Table 58. Novartis Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 59. Novartis Recent Development
Table 60. Bristol-Myers Squibb Company Detail
Table 61. Bristol-Myers Squibb Business Overview
Table 62. Bristol-Myers Squibb Oncology Drugs Product
Table 63. Bristol-Myers Squibb Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 64. Bristol-Myers Squibb Recent Development
Table 65. Johnson & Johnson Company Detail
Table 66. Johnson & Johnson Business Overview
Table 67. Johnson & Johnson Oncology Drugs Product
Table 68. Johnson & Johnson Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 69. Johnson & Johnson Recent Development
Table 70. Merck & Co. Company Detail
Table 71. Merck & Co. Business Overview
Table 72. Merck & Co. Oncology Drugs Product
Table 73. Merck & Co. Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 74. Merck & Co. Recent Development
Table 75. AstraZeneca Company Detail
Table 76. AstraZeneca Business Overview
Table 77. AstraZeneca Oncology Drugs Product
Table 78. AstraZeneca Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 79. AstraZeneca Recent Development
Table 80. Pfizer Company Detail
Table 81. Pfizer Business Overview
Table 82. Pfizer Oncology Drugs Product
Table 83. Pfizer Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 84. Pfizer Recent Development
Table 85. Amgen Company Detail
Table 86. Amgen Business Overview
Table 87. Amgen Oncology Drugs Product
Table 88. Amgen Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 89. Amgen Recent Development
Table 90. Eli Lilly Company Detail
Table 91. Eli Lilly Business Overview
Table 92. Eli Lilly Oncology Drugs Product
Table 93. Eli Lilly Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 94. Eli Lilly Recent Development
Table 95. AbbVie Company Detail
Table 96. AbbVie Business Overview
Table 97. AbbVie Oncology DrugsProduct
Table 98. AbbVie Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 99. AbbVie Recent Development
Table 100. Takeda Company Detail
Table 101. Takeda Business Overview
Table 102. Takeda Oncology DrugsProduct
Table 103. Takeda Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 104. Takeda Recent Development
Table 105. Astellas Company Detail
Table 106. Astellas Business Overview
Table 107. Astellas Oncology DrugsProduct
Table 108. Astellas Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 109. Astellas Recent Development
Table 110. Ipsen Company Detail
Table 111. Ipsen Business Overview
Table 112. Ipsen Oncology DrugsProduct
Table 113. Ipsen Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 114. Ipsen Recent Development
Table 115. Sanofi Company Detail
Table 116. Sanofi Business Overview
Table 117. Sanofi Oncology DrugsProduct
Table 118. Sanofi Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 119. Sanofi Recent Development
Table 120. Bayer Company Detail
Table 121. Bayer Business Overview
Table 122. Bayer Oncology DrugsProduct
Table 123. Bayer Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 124. Bayer Recent Development
Table 125. Biogen Idec Company Detail
Table 126. Biogen Idec Business Overview
Table 127. Biogen Idec Oncology DrugsProduct
Table 128. Biogen Idec Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 129. Biogen Idec Recent Development
Table 130. Teva Company Detail
Table 131. Teva Business Overview
Table 132. Teva Oncology DrugsProduct
Table 133. Teva Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 134. Teva Recent Development
Table 135. Otsuka Company Detail
Table 136. Otsuka Business Overview
Table 137. Otsuka Oncology DrugsProduct
Table 138. Otsuka Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 139. Otsuka Recent Development
Table 140. Eisai Company Detail
Table 141. Eisai Business Overview
Table 142. Eisai Oncology DrugsProduct
Table 143. Eisai Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 144. Eisai Recent Development
Table 145. Merck KGaA Company Detail
Table 146. Merck KGaA Business Overview
Table 147. Merck KGaA Oncology DrugsProduct
Table 148. Merck KGaA Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 149. Merck KGaA Recent Development
Table 150. Gilead Sciences Company Detail
Table 151. Gilead Sciences Business Overview
Table 152. Gilead Sciences Oncology DrugsProduct
Table 153. Gilead Sciences Revenue in Oncology Drugs Business (2017-2022) & (US$ Million)
Table 154. Gilead Sciences Recent Development
Table 155. Roche Company Information
Table 156. Roche Business Overview
Table 157. Roche Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 158. Roche Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 159. Roche Recent Development
Table 160. Celgene Company Information
Table 161. Celgene Business Overview
Table 162. Celgene Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 163. Celgene Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 164. Celgene Recent Development
Table 165. Novartis Company Information
Table 166. Novartis Business Overview
Table 167. Novartis Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 168. Novartis Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 169. Novartis Recent Development
Table 170. Bristol-Myers Squibb Company Information
Table 171. Bristol-Myers Squibb Business Overview
Table 172. Bristol-Myers Squibb Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 173. Bristol-Myers Squibb Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 174. Bristol-Myers Squibb Recent Development
Table 175. Johnson & Johnson Company Information
Table 176. Johnson & Johnson Business Overview
Table 177. Johnson & Johnson Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 178. Johnson & Johnson Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 179. Johnson & Johnson Recent Development
Table 180. Merck & Co. Company Information
Table 181. Merck & Co. Business Overview
Table 182. Merck & Co. Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 183. Merck & Co. Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 184. Merck & Co. Recent Development
Table 185. AstraZeneca Company Information
Table 186. AstraZeneca Business Overview
Table 187. AstraZeneca Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 188. AstraZeneca Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 189. AstraZeneca Recent Development
Table 190. Pfizer Company Information
Table 191. Pfizer Business Overview
Table 192. Pfizer Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 193. Pfizer Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 194. Pfizer Recent Development
Table 195. Amgen Company Information
Table 196. Amgen Business Overview
Table 197. Amgen Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 198. Amgen Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 199. Amgen Recent Development
Table 200. Eli Lilly Company Information
Table 201. Eli Lilly Business Overview
Table 202. Eli Lilly Oncology Drugs Revenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 203. Eli Lilly Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 204. Eli Lilly Recent Development
Table 205. AbbVie Company Information
Table 206. AbbVie Business Overview
Table 207. AbbVie Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 208. AbbVie Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 209. AbbVie Recent Development
Table 210. Takeda Company Information
Table 211. Takeda Business Overview
Table 212. Takeda Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 213. Takeda Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 214. Takeda Recent Development
Table 215. Astellas Company Information
Table 216. Astellas Business Overview
Table 217. Astellas Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 218. Astellas Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 219. Astellas Recent Development
Table 220. Ipsen Company Information
Table 221. Ipsen Business Overview
Table 222. Ipsen Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 223. Ipsen Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 224. Ipsen Recent Development
Table 225. Sanofi Company Information
Table 226. Sanofi Business Overview
Table 227. Sanofi Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 228. Sanofi Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 229. Sanofi Recent Development
Table 230. Bayer Company Information
Table 231. Bayer Business Overview
Table 232. Bayer Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 233. Bayer Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 234. Bayer Recent Development
Table 235. Biogen Idec Company Information
Table 236. Biogen Idec Business Overview
Table 237. Biogen Idec Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 238. Biogen Idec Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 239. Biogen Idec Recent Development
Table 240. Teva Company Information
Table 241. Teva Business Overview
Table 242. Teva Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 243. Teva Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 244. Teva Recent Development
Table 245. Otsuka Company Information
Table 246. Otsuka Business Overview
Table 247. Otsuka Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 248. Otsuka Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 249. Otsuka Recent Development
Table 250. Eisai Company Information
Table 251. Eisai Business Overview
Table 252. Eisai Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 253. Eisai Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 254. Eisai Recent Development
Table 255. Merck KGaA Company Information
Table 256. Merck KGaA Business Overview
Table 257. Merck KGaA Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 258. Merck KGaA Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 259. Merck KGaA Recent Development
Table 260. Gilead Sciences Company Information
Table 261. Gilead Sciences Business Overview
Table 262. Gilead Sciences Oncology DrugsRevenue in Oncology Drugs Business (2018-2023) & (US$ Million)
Table 263. Gilead Sciences Revenue in Oncology Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 264. Gilead Sciences Recent Development
Table 265. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Oncology Drugs Product Picture
Figure 5. Global Oncology Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Oncology Drugs Market Share by Type: 2022 VS 2029
Figure 7. Chemotherapy Product Picture
Figure 8. Targeted Therapy Product Picture
Figure 9. Immunotherapy (Biologic Therapy) Product Picture
Figure 10. Hormonal Therapy Product Picture
Figure 11. Others Product Picture
Figure 12. Global Oncology Drugs Market Size by Application (2023-2029) & (US$ Million)
Figure 13. Global Oncology Drugs Market Share by Application: 2022 VS 2029
Figure 14. Blood Cancer Product Picture
Figure 15. Breast Cancer Product Picture
Figure 16. Gastrointestinal Cancer Product Picture
Figure 17. Prostate Cancer Product Picture
Figure 18. Respiratory or Lung Cancer Product Picture
Figure 19. Others Product Picture
Figure 20. Global Oncology Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 21. Global Oncology Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 22. Global Oncology Drugs Market Share by Region: 2022 VS 2029
Figure 23. Global Oncology Drugs Market Share by Players in 2022
Figure 24. Global Oncology Drugs Players, Date of Enter into This Industry
Figure 25. Global Top 5 and 10 Oncology Drugs Players Market Share by Revenue in 2022
Figure 26. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 27. North America Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. North America Oncology Drugs Market Share by Country (2018-2029)
Figure 29. United States Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Canada Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Europe Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Europe Oncology Drugs Market Share by Country (2018-2029)
Figure 33. Germany Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. France Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. U.K. Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Italy Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Russia Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Nordic Countries Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Asia-Pacific Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Asia-Pacific Oncology Drugs Market Share by Country (2018-2029)
Figure 41. China Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Japan Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Latin America Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Latin America Oncology Drugs Market Share by Country (2018-2029)
Figure 49. Mexico Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Brazil Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Middle East & Africa Oncology Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Middle East & Africa Oncology Drugs Market Share by Country (2018-2029)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings